MedTrace Logo

OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

NCT05222113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2022-02-03

No results posted yet for this study

Summary

In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021

Conditions

  • Duration of Hospitalization
  • Clinical Manifestation of COVID-19

Interventions

DRUG

Remdesivir

The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.

Sponsors & Collaborators

  • Bernadette Dian Novita, MD.,PhD

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
97 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2021-09-25
Completion
2021-09-25

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222113 on ClinicalTrials.gov